EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery

Dong Woog Yoon, Soohyun Hwang, Boram Lee, Yeong Jeong Jeon, Junghee Lee, Dong Wook Shin, Byeong-Ho Jeong, Seong Yong Park, Hong Kwan Kim, Yong Soo Choi, Jong Ho Cho

Cancer Treatment and Research Communications · 2025

DOI: 10.1016/j.ctarc.2025.101014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Dong Woog Yoon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Chung-ang University Hospital, Seoul, South Korea; Department of Thoracic and Cardiovascular Surge…. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Adenocarcinoma, Mucinous, Lung Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chung-Ang University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Invasive mucinous adenocarcinoma (IMA) is genetically distinct from non-mucinous adenocarcinoma, commonly characterized by KRAS mutations. However, studies exploring molecular co-alterations alongside KRAS mutations in IMA remain limited. METHODS: We reviewed 84 patients with surgically resected IMAs from 2015 to 2023 who underwent NGS using TruSight™ Oncology 500 or CancerSCAN assays. Overall survival (OS) and disease-free survival (DFS) were assessed using Cox regression, and log-rank tests were used to evaluate the prognostic role of each molecular alteration. RESULTS: Among the 84 patients, driver alterations were identified in KRAS (67.9 %, n = 57), ERBB2 (10.7 %, n = 9), and NRG-1 (7.1 %, n = 6), while concurrent mutations were found in TP53 (31 %, n = 26), NKX2-1 (23.8 %, n = 20), CDKN2A (15.5 %, n = 13), and PIK3CA (10.7 %, n = 9). Among the overall cohort, survival analysis demonstrated that TP53 alterations were associated with worse OS (p = 0.03), while NKX2-1 alterations were linked to better DFS (p = 0.03). In the KRAS-mutant subgroup, TP53 alterations were associated with worse OS (p < 0.01) and DFS (p < 0.01), while NKX2-1 mutations were associated with better OS (p = 0.05). Multivariate analysis identified TP53 alterations as independent prognostic factors for OS (HR,11.32; 95 % CI,2.18-58.75) and DFS (HR,4.33; 95 % CI,1.84-10.2) in patients with KRAS mutations. CONCLUSION: Concurrent TP53 mutations have significant prognostic implications in KRAS-mutant IMAs. This finding underscores the potential role of TP53 mutations in guiding personalized treatment approaches to improve patient outcomes. MICRO ABSTRACT: In a retrospective cohort of 84 resected pulmonary invasive mucinous adenocarcinomas, next-generation sequencing was performed and genomic alterations were correlated with prognosis. KRAS was the predominant driver (∼68 %), and concurrent TP53 mutations (∼32 %) independently predicted worse overall and disease-free survival within KRAS-mutant IMA. TP53 co-mutation serves as a practical risk stratifier to inform closer post-surgical surveillance and potential adjuvant strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)Adenocarcinoma, MucinousLung NeoplasmsHumansMaleFemaleMiddle AgedAgedMutationPrognosisRetrospective StudiesAdultAged, 80 and overClinical Relevance

Stichwörter der Autor:innen

Invasive mucinous adenocarcinomaKRAS mutationPrognosisTP53 mutation

Substanzen

Tumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)KRAS protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Department of Thoracic and Cardiovascular Surgery, Chung-ang University Hospital, Seoul, South Korea; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine…
  • Lunit Inc., Seoul, South Korea; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Pathology Center, Shinwon Medical Foundation, G…
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Supportive Care Center/ Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Förderung

  • Chung-Ang University

Zitieren

APA

Yoon, D. W., Hwang, S., Lee, B., Jeon, Y. J., Lee, J., Shin, D. W., Jeong, B. H., Park, S. Y., Kim, H. K., Choi, Y. S., & Cho, J. H. (2025). Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.101014

Vancouver

Yoon DW, Hwang S, Lee B, Jeon YJ, Lee J, Shin DW, et al. Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.101014

BibTeX
@article{Yoon2025,
  author = {Yoon, Dong Woog and Hwang, Soohyun and Lee, Boram and Jeon, Yeong Jeong and Lee, Junghee and Shin, Dong Wook and Jeong, Byeong-Ho and Park, Seong Yong and Kim, Hong Kwan and Choi, Yong Soo and Cho, Jong Ho},
  title = {Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  doi = {10.1016/j.ctarc.2025.101014}
}
Kostenlos starten →